DDR

News alerts, weekly reports and conference planners

DDR	Prostate Cancer	DDR	Prostate Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
DDR	Cervical Cancer	DDR	Cervical Cancer	BAY 1895344 Sensitive: C2 – Inclusion Criteria BAY 1895344 Sensitive : C2	BAY 1895344 Sensitive: C2 – Inclusion Criteria BAY 1895344 Sensitive : C2
DDR	Non Small Cell Lung Cancer	DDR	Non Small Cell Lung Cancer	PD-L1 inhibitor + CTLA4 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor + CTLA4 inhibitor Sensitive : C3	PD-L1 inhibitor + CTLA4 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor + CTLA4 inhibitor Sensitive : C3
DDR	Non Small Cell Lung Cancer	DDR	Non Small Cell Lung Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
DDR	Cholangiocarcinoma	DDR	Cholangiocarcinoma	lenvatinib + toripalimab-tpzi Sensitive: C3 – Early Trials lenvatinib + toripalimab-tpzi Sensitive : C3	lenvatinib + toripalimab-tpzi Sensitive: C3 – Early Trials lenvatinib + toripalimab-tpzi Sensitive : C3
DDR	Colorectal Cancer	DDR	Colorectal Cancer	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
DDR	Colorectal Cancer	DDR	Colorectal Cancer	FOLFOX Sensitive: C3 – Early Trials FOLFOX Sensitive : C3	FOLFOX Sensitive: C3 – Early Trials FOLFOX Sensitive : C3
DDR	Colorectal Cancer	DDR	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
DDR	Triple Negative Breast Cancer	DDR	Triple Negative Breast Cancer	pembrolizumab + niraparib Sensitive: C3 – Early Trials pembrolizumab + niraparib Sensitive : C3	pembrolizumab + niraparib Sensitive: C3 – Early Trials pembrolizumab + niraparib Sensitive : C3
DDR	Prostate Cancer	DDR	Prostate Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
DDR	Prostate Cancer	DDR	Prostate Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
DDR	Prostate Cancer	DDR	Prostate Cancer	abiraterone acetate + prednisone Resistant: C3 – Early Trials abiraterone acetate + prednisone Resistant : C3	abiraterone acetate + prednisone Resistant: C3 – Early Trials abiraterone acetate + prednisone Resistant : C3

DDR

Associations